



**Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group**

**Summary of Main Points from the Meeting held on
Monday 15th December 2025**

2. Minutes and Summary Notes from last meeting

This meeting was held via Teams. The Minutes and Summary notes of the Medicines Group Meeting held on 24th October 2025 were approved. The summary notes will be disseminated and published on the Trust intranet. A quarterly summary report will be drafted and forwarded to the Trust Patient Safety Group meeting for inclusion on the agenda in due course.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

4.1 Formulary Applications

Full Applications

• **Levothyroxine 200microgram/ml solution for Injection (Levothyroxine SERB)**

Requested by: Endocrinology

Indication: Treatment of Myxoedema coma and hypothyroidism where oral therapy is not feasible

Also requesting in light of current manufacturing delay with Liothyronine IV.

Proposal: Add to the formulary for ongoing use in light of manufacturers delay with liothyronine (ongoing to April 2026), lower acquisition costs ease of use: No requirement for cardiac monitoring.

Cost implications: Cost saving: Levothyroxine IV £130 vs Liothyronine IV £364 per ampoule.

Outcome: Approved for addition to the formulary

• **Ceftolozane with Tazobactam 1g/0.5g solution for Infusion (Zerbaxa®)**

Requested by: Antimicrobial Stewardship Team

Indication: Treatment of multi-drug resistant Pseudomonas infection when alternative, more cost effective options, are not available.

Proposal: Add to the formulary to use as Cefidericol sparing option (more cost effective and reduces selection of carbapenemase producing organisms compared).

Cost implications: Cost saving: Cefidericol daily dosing 2g TDS = £550 /per day vs Ceftolazone/tazobactam 3g TDS = £484 /per day

Outcome: Approved for addition to the formulary

Short Applications

• **Aflibercept 40mg/ml pre-filled syringe (Vgenfil®)**

Requested by: Ophthalmology

Indication: Treatment of wet age-related macular degeneration (AMD) and visual impairment due to diabetic macular oedema. (First Line Option)

Proposal: Add to the formulary in line with the Trust decision to switch to the Biosimilar Vgenfil® as the biosimilar of choice for Alibercept, replacing the Eylea® brand.

This change is to support the cost effective use of medicines agenda providing savings to the commissioners.

Cost implications: Cost saving of £270 cost saving per unit.

Based on last year's usage. Switching over all patients to using biosimilar will result in a cost saving of £471K per annum.

Outcome: Approved for addition to the formulary

• **Ranibizumab 10mg/ml solution for Injection (Ongavia®)**

Requested by: Ophthalmology



Indication: Treatment of wet age-related macular degeneration (AMD) and visual impairment due to diabetic macular oedema. (First Line Option)

Proposal: Add to the formulary in line with the Trust decision to switch to the Biosimilar Ongavia® as the biosimilar of choice for Ranibizumab, replacing the Lucentis® brand.

This change is to support the cost effective use of medicines agenda providing savings to the commissioners.

Cost implications: Cost saving of £206 per unit.

Lucentis = £316 per unit vs Ongavia = £110 per unit

Outcome: Approved for addition to the formulary

- **Aflibercept 114.3mg/ml (8mg) pre-filled syringe (Eylea®)**

Requested by: Ophthalmology

Indication: Treatment of wet age-related macular degeneration (AMD) and visual impairment due to diabetic macular oedema.

Proposal: Add new formulation onto the formulary as the 2nd line option in line with NICE TA294 and TA346 and NHS England Commissioning Guidance.

Use in patients with high injection frequency with first line options.

This change is to support the cost effective use of medicines agenda providing savings to the commissioners.

Cost implications: Aflibercept 114.3mg/ml (8mg) £247 per unit vs Faricimab £298 per unit

Outcome: Approved for addition to the formulary

Approvals by NWL ICB JFC

- **Drospirenone 4mg Tablets (Slynd®)**

Requested by: London North West with support from CWFT

Indication: Contraception

Proposal: Add to NWL IF as a second line option after first line option Desogestrel

RAG Rating: Green

Proposal: Add to the formulary in line with NWL ICB JF Committee decision.

Outcome: Approved for addition to the formulary

NICE TA Applications

- **TA1106 Cabotegravir for preventing HIV-1 in adults and young people (05/11/2025)**

Proposal: Add to the formulary in line with NICE TA1106

Outcome: Approved for addition to the formulary

- **TA1107 Delgocitinib for treating moderate to severe chronic hand eczema (05/11/2025)**

Proposal: Add to the formulary in line with NICE TA1107

Outcome: Approved for addition to the formulary

Pharmacoeconomic Board Applications

- **Trientene for Wilsons Disease**

Approved by Pharmacoeconomic Board on 13/11/2025 - For noting

Outcome: Noted

- **Olaparib for Breast CA**

Approved by Pharmacoeconomic Board on 13/11/2025 - For noting

Outcome: Noted

Removals

- Ephedrine Hydrochloride 0.5% Nasal Spray
- Meningococcal Group C Conjugated Vaccine
- Alphosyl 2 in 1 Shampoo
- Haemophilus Influenza Type B Vaccine

Proposal: Remove from the formulary as all discontinued by manufacturers

Outcome: Approved for removal from the formulary



4.2 Trust Medicines Policy

- **TMP: Section 2 - Prescribing of medicines**

Routine review and update

- Removal of all references to paper drug charts
- Update in light of transition from Aria to ChemoCare for chemotherapy prescribing.
- Clarification of prescribing and validation of SACT for cancer and non-cancer indications
- Clarification of validity of repeat out-patient prescriptions

Outcome: Approved

- **TMP: Section 8 - Administration of medicines**

Section 8.15 relating to covert medicines administration updated in collaboration with the CNL for Mental Health

Outcome: Approved

- **TMP: Section: 34 - Supply and administration of medicines by Non-registered Healthcare Practitioners**

Addition:

- Administration of the following by Healthcare Assistants, Assistant Practitioners and Health Advisors within the HIV/GUM Directorate:
 - Meningococcal Group B Vaccine (rDNA, component, adsorbed) (Bexsero®)
 - Hepatitis A Virus (Inactivated) and Hepatitis B Virus (rDNA) (HAB) Vaccine (absorbed) (Twinrix®)

Outcome: Approved

4.3 Medicines Optimisation

- **NHS England: Principles for using biosimilar medicines**

NHS England guidance on appropriate use of biosimilar medicines

Outcome: Noted

4.4 NICE Technical Appraisals and Guidance

14 TA appraisals published since previous TMG meeting to December 2025

- **TA1099 Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy (01/10/2025)**

Formulary status / Action

Included on the formulary for another indication

Numbers likely to treat at CWH site: 1 patient per year

Numbers likely to treat at WMUH site: 1 patient per year

- **TA1100 Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (01/10/2025)**

Formulary status / Action

Nil - Terminated Appraisal

- **TA1101 Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over (08/10/2025)**

Formulary status / Action

Not included on the formulary

Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site

- **TA1102 Iptacopan for treating complement 3 glomerulopathy (terminated appraisal) (29/10/2025)**

Formulary status / Action

Nil - Terminated Appraisal

- **TA1103 Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor (21/10/2025)**

Formulary status / Action

Included on the formulary for another indication



Numbers likely to treat at CWH site: 1 patient per year
Numbers likely to treat at WMUH site: 1 patient per year

- TA1104 Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years

Formulary status / Action

Nil - Terminated Appraisal

- TA1105 Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal) (22/10/2025)

Formulary status / Action

Nil - Terminated Appraisal

- TA1106 Cabotegravir for preventing HIV-1 in adults and young people (05/11/2025)

Formulary status / Action

Not included on the formulary

Application form received - See Section 4.1

- TA1107 Delgocitinib for treating moderate to severe chronic hand eczema (05/11/2025)

Formulary status / Action

Not included on the formulary

Application form received - See Section 4.1

- TA1108 Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer (05/11/2025)

Formulary status / Action

Nil - Not recommended

- TA1109 Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (12/11/2025)

Formulary status / Action

Included on the formulary for another indication

Numbers likely to treat at CWH site: __ patients per year

Numbers likely to treat at WMUH site: __ patients per year

- TA1110 Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (19/11/2025)

Formulary status / Action

Included on the formulary for another indication

Numbers likely to treat at CWH site: 1-2 patients per year

Numbers likely to treat at WMUH site: 0 patient per year

- TA1111 Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (19/11/2025)

Formulary status / Action

Nil - Terminated Appraisal

- TA1112 Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (19/11/2025)

Formulary status / Action

Nil - Terminated Appraisal

b) NICE Highly Specialised Technology Appraisals published since last meeting
0 HST appraisal published since previous TMG meeting to December 2025

4.5 Items for noting

- Quarterly Controlled Drug Summary Report - Q1 2025/26

Quarterly Controlled Drug Summary Report for Q1 2025/26



Outcome: Noted

- **Quarterly Controlled Drugs Accountable Officer Report - Q1 2025/26**

Quarterly CD Accountable Officer Report for Q1 2025/26

Outcome: Noted

- **PGD/WI/Protocol Log - December 2025**

Log of Patient Group Directions/Written Instruction and Protocols as of December 2025

Total: 120

No due to expire before end Dec: 3

Outcome: Noted

- **Medication Safety Bulletin: GLP-1 Receptor Agonists**

Medication Safety Bulletin relating to GLP-1 Receptor Agonists

Outcome: Noted

- **Medication Safety Bulletin: End of Life Care and Palliative Care**

Medication Safety Bulletin relating to End of Life Care and Palliative Care

Outcome: Noted

- **MHRA Drug Safety Round-up - October 2025**

MHRA round-up for October 2025

Outcome: Noted

- **MHRA Drug Safety Round-up - November 2025**

MHRA round-up for November 2025

Outcome: Noted

4.6 Meeting minutes for noting

- **HIV, Sexual Health and Gender Health Medicines Sub-Group - Terms of Reference - December 2025**

Terms of Reference for HIV, Sexual Health and Gender Health Medicines Sub-Group - December 2025

Outcome: Noted

- **HIV, Sexual Health and Gender Health Medicines Sub-Group Meeting Minutes - October 2025**

Minutes from HIV, Sexual Health and Gender Health Medicines Sub-Group Meeting held October 2025

Outcome: Noted

- **Medicines Optimisation Group - Terms of Reference - December 2025**

Terms of Reference for Medicines Optimisation Group - December 2025

Outcome: Noted

- **Medication Safety Group Meeting Minutes - October 2025**

Minutes from Trust Medication Safety Group Meeting held October 2025

Outcome: Noted

- **NWL ICB Joint Formulary Committee Meeting Minutes - September 2025**

Minutes from NWL ICB Joint Formulary Committee Meeting held September 2025

Outcome: Noted

5. Any other business

Nil

6. Date of next meeting

Meetings Dates for 2026



Date: TBC
Time: 8am-9am
Location: via Teams